Abstract
In the setting of increasing prevalence of co-existing malignancy and abdominal aortic aneurysmal (AAA) disease, Becker von Rose et al. address a clinically relevant topic.1 To date, patients presenting with concomitant cancer and AAA should not undergo prophylactic aneurysm repair for different indications from patients without cancer.2 A few limited series have reported the effect of cytotoxic chemotherapy on AAA growth, and the follow up in this subset of patients remains non-standardised. The present study, which includes the largest number of aneurysms in oncological patients, might fill this gap and help in stratifying the AAA growth rate estimate in such settings.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
